Furthermore, CTLA-4 inhibitors have been demonstrated to deplete Tregs in the TME and enhance cytotoxic T lymphocyte (CTL)-mediated anti-tumor immunity through enhanced antigen recoginition [45]. Here, CTLA4 is linked to neoplasm.